Table 1 Demographic and clinical characteristics of the rheumatoid arthritis patients from the “Hospital Clínico San Carlos - Rheumatoid Arthritis Cohort” and from the “Hospital Universitario de La Princesa Early Arthritis Register Longitudinal” with more than 2 years of follow-up after disease diagnosis.

From: Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach

Variables

HCSC-RAC

PEARL

n = 1,461

Missing data, n (%)

n = 280

Missing data, n (%)

Women, n (%)

1,105 (75.6)

0

223 (79.6)

0

Age of RA diagnosis, median (IQR)

58.6 (45.2–72.0)

0

54.9 (45.3–67.6)

0

Elapsed time from RA symptoms onset to diagnosis, in years, median (IQR)

0.7 (0.3 to 3.5)

180 (12.3)

0.5 (0.3–0.7)

0

Presence of Rheumatoid Factor, n (%)

885 (61.5)

23 (1.6)

181 (64.6)

0

Presence of ACPA, n (%)

465 (44.9)

425 (29.1)

234 (83.9)

1 (0.4)

Nationality, n (%):

 

0

 

0

  Spanish

1,160 (79.4)

232 (82.7)

  South/Centre America, Caribbean

237 (16.2)

37 (13.2)

  Other

64 (4.4)

11 (3.9)

Year of RA diagnosis, n (%):

 

0

 

0

2001–2005

614 (42.0)

107 (38.2)

2006–2011

847 (58.0)

128 (45.7)

2012–2014

0

 

45 (16.1)

Median HAQ in the first 2 years after RA diagnosis, median (IQR)

0.50 (0.19–1.10)

376 (25.7)

0.63 (0.25–1.00)

1 (0.4)

Median ESR in the first 2 years after RA diagnosis, median (IQR)

23 (14 to 36.5)

248 (17.0)

20 (13–30)

1 (0.4)

Any biological therapy in the first 2 years after RA diagnosis, n (%)

89 (6.1)

0

28 (10.0)

0

Hospital admissions in the first 2 years after RA diagnosis, n (%)

 

0

 

13 (4.6)

  0

1,258 (86.1)

230 (86.1)

  1

144 (9.9)

28 (10.5)

  2

39 (2.7)

5 (1.87)

  3

16 (1.1)

2 (0.8)

≥4

4 (0.28)

2 (0.8)

Inclusion period, calendar years

2001–2011

2001–2014

  1. ACPA: Anti-citrullinated peptides antibodies, ESR: Erythrocyte sedimentation rate, HAQ: Health assessment questionnaire, IQR: Interquartile range, RA: Rheumatoid Arthritis.